Year-End Report 21/22

September 2021 – August 2022, Diamyd Medical AB (publ), Fiscal year 2021/2022Transformational Precision Medicine for Type 1 DiabetesTherapeutic diabetes vaccine Diamyd[®] in pivotal Phase 3 trial Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2021 – August 31, 2022 · Net result: MSEK -103.5 (60.0), fourth quarter: MSEK -36.7 (-27.4). The previous year includes a one-off effect of corresponding MSEK 144.4 from divestment of shares in Companion Medical, Inc.